+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Urokinase Market - Global Forecast 2026-2032- Product Image
Urokinase Market - Global Forecast 2026-2032- Product Image
New

Urokinase Market - Global Forecast 2026-2032

  • PDF Icon

    Report

  • 194 Pages
  • January 2026
  • Region: Global
  • 360iResearch™
  • ID: 4995126
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

The urokinase market stands at the intersection of biotechnology advancements and evolving clinical pathways, supporting critical therapies across acute care and surgical protocols. As demand rises for effective thrombolytic solutions, the sector’s innovation and regulatory agility are shaping procurement strategies for hospitals and pharmaceutical leaders seeking operational reliability and clinical excellence.

Market Snapshot: Urokinase Market Growth and Outlook

The urokinase market is projected to grow from USD 1.95 billion in 2025 to USD 2.07 billion in 2026, with a compound annual growth rate (CAGR) of 6.92%, reaching USD 3.12 billion by 2032. Growth trends reflect continuous advancements in production technologies, increased demand for efficient thrombolytic agents, adaptations in supply-chain management, and broader adoption across acute and elective medical pathways. These factors are fostering a robust environment for pharmaceutical manufacturers, procurement specialists, and hospital decision-makers to reassess market opportunities and risk mitigation in the evolving regulatory and competitive landscape.

Scope & Segmentation of the Urokinase Market

  • Product Types: Distinction between human-derived and recombinant urokinase, underlining influences on purity standards, consistency of supply, and immunogenicity risk management.
  • Expression Platforms: Examination of Escherichia coli and mammalian cell expression systems, with each platform directly impacting glycosylation profiles, impurity levels, and downstream purification strategies.
  • Formulation Formats: Analysis of liquid solution and powder forms, focusing on cold-chain logistics, shelf-life stability, and administration nuances important for care delivery.
  • Clinical Applications: Coverage extends to cardiovascular and vascular surgery uses, acute thrombolytic therapy, and time-sensitive emergency interventions, reflecting the clinical settings where urokinase’s value is realized.
  • End Users: Profiles include hospitals, specialty clinics, ambulatory surgical centers, and diagnostic centers, highlighting diverse procurement volumes and workflow requirements based on care complexity.
  • Distribution Channels: Assessment of access dynamics via hospital pharmacies, retail outlets, and online platforms, expanding reach and supply assurance for various healthcare systems.
  • Regions Covered: Strategic considerations for the Americas, Europe, Middle East & Africa, and Asia-Pacific, each shaped by nuanced regulatory environments, manufacturing capabilities, and market access conditions.

This comprehensive segmentation approach enables senior stakeholders to align investments and market entry strategies with clinical needs, technology evolution, and region-specific opportunities.

Key Takeaways: Strategic Insights for Decision-Makers

  • Recombinant production supports consistency in batch quality and enhances reliability of supply, prompting broader integration in acute and ambulatory care settings.
  • Regionalized logistics and distribution nodes help mitigate risk of external trade disruptions and variable regulatory oversight, strengthening operational continuity.
  • Powder and pre-filled formulations are increasingly adopted due to better shelf stability and improved workflow integration in emergency and elective care environments.
  • Adoption of catheter-based delivery approaches is shaping urokinase utilization, requiring customized workflows tailored to perioperative and emergency procedures.
  • Enhanced pharmacovigilance and quality assurance protocols respond to increased regulatory scrutiny in biologics, reinforcing trust and compliance among healthcare partners.
  • Strategic partnerships in manufacturing and supply agreements drive market entry speed and boost resilience during regional or global disruptions.

Tariff Impact on Urokinase Supply Chains and Procurement

Recent US tariff adjustments are prompting manufacturers and distributors to revisit procurement and supply models. Upstream duties directly influence operational expenditures, fostering trends toward vertical integration, regionalized supply, and contingency planning. For hospital systems and pharmacies, procurement decisions must now account for budget constraints and the imperative of uninterrupted patient care, while simultaneously adapting strategies to evolving cost structures and supplier relationships.

Methodology & Data Sources

The insights presented draw on structured interviews with clinicians, pharmacists, manufacturing specialists, and supply-chain experts, backed by detailed reviews of regulatory submissions and manufacturing standards. Secondary research incorporates peer-reviewed literature, regulatory documents, and relevant case studies to validate findings and support actionable recommendations.

Why This Report Matters for Senior Decision-Makers

  • Clarifies the segmentation and product innovation factors most relevant to procurement and investment decision-making.
  • Distills the impact of regulatory and manufacturing shifts on risk exposure and sustainability planning.
  • Bridges clinical and operational advances to strengthen supply-chain and distribution strategy across multiple care environments.

Urokinase Market: Evidence-Based Insights for Leaders

By focusing on comprehensive benchmarking and verifiable market analysis, this report equips senior leaders with the clarity needed to guide procurement, investment, and supply-chain priorities in a complex, evolving urokinase market.

Conclusion

Navigating the urokinase market requires coordinated investments in manufacturing, regulatory engagement, and responsive distribution. Strategic alignment in these areas delivers consistent access and enhances both clinical and operational outcomes across a dynamic healthcare ecosystem.

 

Additional Product Information:

  • Purchase of this report includes 1 year online access with quarterly updates.
  • This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Definition
1.3. Market Segmentation & Coverage
1.4. Years Considered for the Study
1.5. Currency Considered for the Study
1.6. Language Considered for the Study
1.7. Key Stakeholders
2. Research Methodology
2.1. Introduction
2.2. Research Design
2.2.1. Primary Research
2.2.2. Secondary Research
2.3. Research Framework
2.3.1. Qualitative Analysis
2.3.2. Quantitative Analysis
2.4. Market Size Estimation
2.4.1. Top-Down Approach
2.4.2. Bottom-Up Approach
2.5. Data Triangulation
2.6. Research Outcomes
2.7. Research Assumptions
2.8. Research Limitations
3. Executive Summary
3.1. Introduction
3.2. CXO Perspective
3.3. Market Size & Growth Trends
3.4. Market Share Analysis, 2025
3.5. FPNV Positioning Matrix, 2025
3.6. New Revenue Opportunities
3.7. Next-Generation Business Models
3.8. Industry Roadmap
4. Market Overview
4.1. Introduction
4.2. Industry Ecosystem & Value Chain Analysis
4.2.1. Supply-Side Analysis
4.2.2. Demand-Side Analysis
4.2.3. Stakeholder Analysis
4.3. Porter’s Five Forces Analysis
4.4. PESTLE Analysis
4.5. Market Outlook
4.5.1. Near-Term Market Outlook (0-2 Years)
4.5.2. Medium-Term Market Outlook (3-5 Years)
4.5.3. Long-Term Market Outlook (5-10 Years)
4.6. Go-to-Market Strategy
5. Market Insights
5.1. Consumer Insights & End-User Perspective
5.2. Consumer Experience Benchmarking
5.3. Opportunity Mapping
5.4. Distribution Channel Analysis
5.5. Pricing Trend Analysis
5.6. Regulatory Compliance & Standards Framework
5.7. ESG & Sustainability Analysis
5.8. Disruption & Risk Scenarios
5.9. Return on Investment & Cost-Benefit Analysis
6. Cumulative Impact of United States Tariffs 2025
7. Cumulative Impact of Artificial Intelligence 2025
8. Urokinase Market, by Product Type
8.1. Human Urokinase
8.2. Recombinant Urokinase
8.2.1. Escherichia Coli Expression
8.2.2. Mammalian Cell Expression
9. Urokinase Market, by Form
9.1. Liquid Solution
9.2. Powder
10. Urokinase Market, by Application
10.1. Cardiovascular Surgery
10.1.1. Coronary Artery Bypass Grafting
10.1.2. Valve Replacement
10.2. Thrombolytic Therapy
10.2.1. Acute Myocardial Infarction
10.2.2. Pulmonary Embolism
11. Urokinase Market, by End User
11.1. Ambulatory Surgical Centers
11.2. Diagnostic Centers
11.3. Hospitals
11.4. Specialty Clinics
12. Urokinase Market, by Distribution Channel
12.1. Hospital Pharmacy
12.2. Online Sales
12.3. Retail Pharmacy
13. Urokinase Market, by Region
13.1. Americas
13.1.1. North America
13.1.2. Latin America
13.2. Europe, Middle East & Africa
13.2.1. Europe
13.2.2. Middle East
13.2.3. Africa
13.3. Asia-Pacific
14. Urokinase Market, by Group
14.1. ASEAN
14.2. GCC
14.3. European Union
14.4. BRICS
14.5. G7
14.6. NATO
15. Urokinase Market, by Country
15.1. United States
15.2. Canada
15.3. Mexico
15.4. Brazil
15.5. United Kingdom
15.6. Germany
15.7. France
15.8. Russia
15.9. Italy
15.10. Spain
15.11. China
15.12. India
15.13. Japan
15.14. Australia
15.15. South Korea
16. United States Urokinase Market
17. China Urokinase Market
18. Competitive Landscape
18.1. Market Concentration Analysis, 2025
18.1.1. Concentration Ratio (CR)
18.1.2. Herfindahl Hirschman Index (HHI)
18.2. Recent Developments & Impact Analysis, 2025
18.3. Product Portfolio Analysis, 2025
18.4. Benchmarking Analysis, 2025
18.5. Cerbios-Pharma SA
18.6. Guangdong Techpool Bio-Pharmaceutical Co., Ltd.
18.7. Hanways Chempharm
18.8. Kraeber & Co GmbH
18.9. LIVZON
18.10. Medac GmbH
18.11. Microbix Biosystems Inc.
18.12. Parchem Fine & Specialty Chemicals
18.13. Taj Pharmaceuticals Ltd.
18.14. Wanhua Biochem
18.15. Zydus
List of Figures
FIGURE 1. GLOBAL UROKINASE MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 2. GLOBAL UROKINASE MARKET SHARE, BY KEY PLAYER, 2025
FIGURE 3. GLOBAL UROKINASE MARKET, FPNV POSITIONING MATRIX, 2025
FIGURE 4. GLOBAL UROKINASE MARKET SIZE, BY PRODUCT TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 5. GLOBAL UROKINASE MARKET SIZE, BY FORM, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 6. GLOBAL UROKINASE MARKET SIZE, BY APPLICATION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 7. GLOBAL UROKINASE MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 8. GLOBAL UROKINASE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 9. GLOBAL UROKINASE MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 10. GLOBAL UROKINASE MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 11. GLOBAL UROKINASE MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 12. UNITED STATES UROKINASE MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 13. CHINA UROKINASE MARKET SIZE, 2018-2032 (USD MILLION)
List of Tables
TABLE 1. GLOBAL UROKINASE MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 2. GLOBAL UROKINASE MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
TABLE 3. GLOBAL UROKINASE MARKET SIZE, BY HUMAN UROKINASE, BY REGION, 2018-2032 (USD MILLION)
TABLE 4. GLOBAL UROKINASE MARKET SIZE, BY HUMAN UROKINASE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 5. GLOBAL UROKINASE MARKET SIZE, BY HUMAN UROKINASE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 6. GLOBAL UROKINASE MARKET SIZE, BY RECOMBINANT UROKINASE, BY REGION, 2018-2032 (USD MILLION)
TABLE 7. GLOBAL UROKINASE MARKET SIZE, BY RECOMBINANT UROKINASE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 8. GLOBAL UROKINASE MARKET SIZE, BY RECOMBINANT UROKINASE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 9. GLOBAL UROKINASE MARKET SIZE, BY RECOMBINANT UROKINASE, 2018-2032 (USD MILLION)
TABLE 10. GLOBAL UROKINASE MARKET SIZE, BY ESCHERICHIA COLI EXPRESSION, BY REGION, 2018-2032 (USD MILLION)
TABLE 11. GLOBAL UROKINASE MARKET SIZE, BY ESCHERICHIA COLI EXPRESSION, BY GROUP, 2018-2032 (USD MILLION)
TABLE 12. GLOBAL UROKINASE MARKET SIZE, BY ESCHERICHIA COLI EXPRESSION, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 13. GLOBAL UROKINASE MARKET SIZE, BY MAMMALIAN CELL EXPRESSION, BY REGION, 2018-2032 (USD MILLION)
TABLE 14. GLOBAL UROKINASE MARKET SIZE, BY MAMMALIAN CELL EXPRESSION, BY GROUP, 2018-2032 (USD MILLION)
TABLE 15. GLOBAL UROKINASE MARKET SIZE, BY MAMMALIAN CELL EXPRESSION, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 16. GLOBAL UROKINASE MARKET SIZE, BY FORM, 2018-2032 (USD MILLION)
TABLE 17. GLOBAL UROKINASE MARKET SIZE, BY LIQUID SOLUTION, BY REGION, 2018-2032 (USD MILLION)
TABLE 18. GLOBAL UROKINASE MARKET SIZE, BY LIQUID SOLUTION, BY GROUP, 2018-2032 (USD MILLION)
TABLE 19. GLOBAL UROKINASE MARKET SIZE, BY LIQUID SOLUTION, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 20. GLOBAL UROKINASE MARKET SIZE, BY POWDER, BY REGION, 2018-2032 (USD MILLION)
TABLE 21. GLOBAL UROKINASE MARKET SIZE, BY POWDER, BY GROUP, 2018-2032 (USD MILLION)
TABLE 22. GLOBAL UROKINASE MARKET SIZE, BY POWDER, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 23. GLOBAL UROKINASE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
TABLE 24. GLOBAL UROKINASE MARKET SIZE, BY CARDIOVASCULAR SURGERY, BY REGION, 2018-2032 (USD MILLION)
TABLE 25. GLOBAL UROKINASE MARKET SIZE, BY CARDIOVASCULAR SURGERY, BY GROUP, 2018-2032 (USD MILLION)
TABLE 26. GLOBAL UROKINASE MARKET SIZE, BY CARDIOVASCULAR SURGERY, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 27. GLOBAL UROKINASE MARKET SIZE, BY CARDIOVASCULAR SURGERY, 2018-2032 (USD MILLION)
TABLE 28. GLOBAL UROKINASE MARKET SIZE, BY CORONARY ARTERY BYPASS GRAFTING, BY REGION, 2018-2032 (USD MILLION)
TABLE 29. GLOBAL UROKINASE MARKET SIZE, BY CORONARY ARTERY BYPASS GRAFTING, BY GROUP, 2018-2032 (USD MILLION)
TABLE 30. GLOBAL UROKINASE MARKET SIZE, BY CORONARY ARTERY BYPASS GRAFTING, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 31. GLOBAL UROKINASE MARKET SIZE, BY VALVE REPLACEMENT, BY REGION, 2018-2032 (USD MILLION)
TABLE 32. GLOBAL UROKINASE MARKET SIZE, BY VALVE REPLACEMENT, BY GROUP, 2018-2032 (USD MILLION)
TABLE 33. GLOBAL UROKINASE MARKET SIZE, BY VALVE REPLACEMENT, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 34. GLOBAL UROKINASE MARKET SIZE, BY THROMBOLYTIC THERAPY, BY REGION, 2018-2032 (USD MILLION)
TABLE 35. GLOBAL UROKINASE MARKET SIZE, BY THROMBOLYTIC THERAPY, BY GROUP, 2018-2032 (USD MILLION)
TABLE 36. GLOBAL UROKINASE MARKET SIZE, BY THROMBOLYTIC THERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 37. GLOBAL UROKINASE MARKET SIZE, BY THROMBOLYTIC THERAPY, 2018-2032 (USD MILLION)
TABLE 38. GLOBAL UROKINASE MARKET SIZE, BY ACUTE MYOCARDIAL INFARCTION, BY REGION, 2018-2032 (USD MILLION)
TABLE 39. GLOBAL UROKINASE MARKET SIZE, BY ACUTE MYOCARDIAL INFARCTION, BY GROUP, 2018-2032 (USD MILLION)
TABLE 40. GLOBAL UROKINASE MARKET SIZE, BY ACUTE MYOCARDIAL INFARCTION, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 41. GLOBAL UROKINASE MARKET SIZE, BY PULMONARY EMBOLISM, BY REGION, 2018-2032 (USD MILLION)
TABLE 42. GLOBAL UROKINASE MARKET SIZE, BY PULMONARY EMBOLISM, BY GROUP, 2018-2032 (USD MILLION)
TABLE 43. GLOBAL UROKINASE MARKET SIZE, BY PULMONARY EMBOLISM, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 44. GLOBAL UROKINASE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 45. GLOBAL UROKINASE MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY REGION, 2018-2032 (USD MILLION)
TABLE 46. GLOBAL UROKINASE MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 47. GLOBAL UROKINASE MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 48. GLOBAL UROKINASE MARKET SIZE, BY DIAGNOSTIC CENTERS, BY REGION, 2018-2032 (USD MILLION)
TABLE 49. GLOBAL UROKINASE MARKET SIZE, BY DIAGNOSTIC CENTERS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 50. GLOBAL UROKINASE MARKET SIZE, BY DIAGNOSTIC CENTERS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 51. GLOBAL UROKINASE MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
TABLE 52. GLOBAL UROKINASE MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 53. GLOBAL UROKINASE MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 54. GLOBAL UROKINASE MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2018-2032 (USD MILLION)
TABLE 55. GLOBAL UROKINASE MARKET SIZE, BY SPECIALTY CLINICS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 56. GLOBAL UROKINASE MARKET SIZE, BY SPECIALTY CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 57. GLOBAL UROKINASE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 58. GLOBAL UROKINASE MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2018-2032 (USD MILLION)
TABLE 59. GLOBAL UROKINASE MARKET SIZE, BY HOSPITAL PHARMACY, BY GROUP, 2018-2032 (USD MILLION)
TABLE 60. GLOBAL UROKINASE MARKET SIZE, BY HOSPITAL PHARMACY, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 61. GLOBAL UROKINASE MARKET SIZE, BY ONLINE SALES, BY REGION, 2018-2032 (USD MILLION)
TABLE 62. GLOBAL UROKINASE MARKET SIZE, BY ONLINE SALES, BY GROUP, 2018-2032 (USD MILLION)
TABLE 63. GLOBAL UROKINASE MARKET SIZE, BY ONLINE SALES, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 64. GLOBAL UROKINASE MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2018-2032 (USD MILLION)
TABLE 65. GLOBAL UROKINASE MARKET SIZE, BY RETAIL PHARMACY, BY GROUP, 2018-2032 (USD MILLION)
TABLE 66. GLOBAL UROKINASE MARKET SIZE, BY RETAIL PHARMACY, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 67. GLOBAL UROKINASE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 68. AMERICAS UROKINASE MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
TABLE 69. AMERICAS UROKINASE MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
TABLE 70. AMERICAS UROKINASE MARKET SIZE, BY RECOMBINANT UROKINASE, 2018-2032 (USD MILLION)
TABLE 71. AMERICAS UROKINASE MARKET SIZE, BY FORM, 2018-2032 (USD MILLION)
TABLE 72. AMERICAS UROKINASE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
TABLE 73. AMERICAS UROKINASE MARKET SIZE, BY CARDIOVASCULAR SURGERY, 2018-2032 (USD MILLION)
TABLE 74. AMERICAS UROKINASE MARKET SIZE, BY THROMBOLYTIC THERAPY, 2018-2032 (USD MILLION)
TABLE 75. AMERICAS UROKINASE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 76. AMERICAS UROKINASE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 77. NORTH AMERICA UROKINASE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 78. NORTH AMERICA UROKINASE MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
TABLE 79. NORTH AMERICA UROKINASE MARKET SIZE, BY RECOMBINANT UROKINASE, 2018-2032 (USD MILLION)
TABLE 80. NORTH AMERICA UROKINASE MARKET SIZE, BY FORM, 2018-2032 (USD MILLION)
TABLE 81. NORTH AMERICA UROKINASE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
TABLE 82. NORTH AMERICA UROKINASE MARKET SIZE, BY CARDIOVASCULAR SURGERY, 2018-2032 (USD MILLION)
TABLE 83. NORTH AMERICA UROKINASE MARKET SIZE, BY THROMBOLYTIC THERAPY, 2018-2032 (USD MILLION)
TABLE 84. NORTH AMERICA UROKINASE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 85. NORTH AMERICA UROKINASE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 86. LATIN AMERICA UROKINASE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 87. LATIN AMERICA UROKINASE MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
TABLE 88. LATIN AMERICA UROKINASE MARKET SIZE, BY RECOMBINANT UROKINASE, 2018-2032 (USD MILLION)
TABLE 89. LATIN AMERICA UROKINASE MARKET SIZE, BY FORM, 2018-2032 (USD MILLION)
TABLE 90. LATIN AMERICA UROKINASE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
TABLE 91. LATIN AMERICA UROKINASE MARKET SIZE, BY CARDIOVASCULAR SURGERY, 2018-2032 (USD MILLION)
TABLE 92. LATIN AMERICA UROKINASE MARKET SIZE, BY THROMBOLYTIC THERAPY, 2018-2032 (USD MILLION)
TABLE 93. LATIN AMERICA UROKINASE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 94. LATIN AMERICA UROKINASE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 95. EUROPE, MIDDLE EAST & AFRICA UROKINASE MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
TABLE 96. EUROPE, MIDDLE EAST & AFRICA UROKINASE MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
TABLE 97. EUROPE, MIDDLE EAST & AFRICA UROKINASE MARKET SIZE, BY RECOMBINANT UROKINASE, 2018-2032 (USD MILLION)
TABLE 98. EUROPE, MIDDLE EAST & AFRICA UROKINASE MARKET SIZE, BY FORM, 2018-2032 (USD MILLION)
TABLE 99. EUROPE, MIDDLE EAST & AFRICA UROKINASE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
TABLE 100. EUROPE, MIDDLE EAST & AFRICA UROKINASE MARKET SIZE, BY CARDIOVASCULAR SURGERY, 2018-2032 (USD MILLION)
TABLE 101. EUROPE, MIDDLE EAST & AFRICA UROKINASE MARKET SIZE, BY THROMBOLYTIC THERAPY, 2018-2032 (USD MILLION)
TABLE 102. EUROPE, MIDDLE EAST & AFRICA UROKINASE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 103. EUROPE, MIDDLE EAST & AFRICA UROKINASE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 104. EUROPE UROKINASE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 105. EUROPE UROKINASE MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
TABLE 106. EUROPE UROKINASE MARKET SIZE, BY RECOMBINANT UROKINASE, 2018-2032 (USD MILLION)
TABLE 107. EUROPE UROKINASE MARKET SIZE, BY FORM, 2018-2032 (USD MILLION)
TABLE 108. EUROPE UROKINASE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
TABLE 109. EUROPE UROKINASE MARKET SIZE, BY CARDIOVASCULAR SURGERY, 2018-2032 (USD MILLION)
TABLE 110. EUROPE UROKINASE MARKET SIZE, BY THROMBOLYTIC THERAPY, 2018-2032 (USD MILLION)
TABLE 111. EUROPE UROKINASE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 112. EUROPE UROKINASE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 113. MIDDLE EAST UROKINASE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 114. MIDDLE EAST UROKINASE MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
TABLE 115. MIDDLE EAST UROKINASE MARKET SIZE, BY RECOMBINANT UROKINASE, 2018-2032 (USD MILLION)
TABLE 116. MIDDLE EAST UROKINASE MARKET SIZE, BY FORM, 2018-2032 (USD MILLION)
TABLE 117. MIDDLE EAST UROKINASE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
TABLE 118. MIDDLE EAST UROKINASE MARKET SIZE, BY CARDIOVASCULAR SURGERY, 2018-2032 (USD MILLION)
TABLE 119. MIDDLE EAST UROKINASE MARKET SIZE, BY THROMBOLYTIC THERAPY, 2018-2032 (USD MILLION)
TABLE 120. MIDDLE EAST UROKINASE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 121. MIDDLE EAST UROKINASE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 122. AFRICA UROKINASE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 123. AFRICA UROKINASE MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
TABLE 124. AFRICA UROKINASE MARKET SIZE, BY RECOMBINANT UROKINASE, 2018-2032 (USD MILLION)
TABLE 125. AFRICA UROKINASE MARKET SIZE, BY FORM, 2018-2032 (USD MILLION)
TABLE 126. AFRICA UROKINASE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
TABLE 127. AFRICA UROKINASE MARKET SIZE, BY CARDIOVASCULAR SURGERY, 2018-2032 (USD MILLION)
TABLE 128. AFRICA UROKINASE MARKET SIZE, BY THROMBOLYTIC THERAPY, 2018-2032 (USD MILLION)
TABLE 129. AFRICA UROKINASE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 130. AFRICA UROKINASE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 131. ASIA-PACIFIC UROKINASE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 132. ASIA-PACIFIC UROKINASE MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
TABLE 133. ASIA-PACIFIC UROKINASE MARKET SIZE, BY RECOMBINANT UROKINASE, 2018-2032 (USD MILLION)
TABLE 134. ASIA-PACIFIC UROKINASE MARKET SIZE, BY FORM, 2018-2032 (USD MILLION)
TABLE 135. ASIA-PACIFIC UROKINASE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
TABLE 136. ASIA-PACIFIC UROKINASE MARKET SIZE, BY CARDIOVASCULAR SURGERY, 2018-2032 (USD MILLION)
TABLE 137. ASIA-PACIFIC UROKINASE MARKET SIZE, BY THROMBOLYTIC THERAPY, 2018-2032 (USD MILLION)
TABLE 138. ASIA-PACIFIC UROKINASE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 139. ASIA-PACIFIC UROKINASE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 140. GLOBAL UROKINASE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 141. ASEAN UROKINASE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 142. ASEAN UROKINASE MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
TABLE 143. ASEAN UROKINASE MARKET SIZE, BY RECOMBINANT UROKINASE, 2018-2032 (USD MILLION)
TABLE 144. ASEAN UROKINASE MARKET SIZE, BY FORM, 2018-2032 (USD MILLION)
TABLE 145. ASEAN UROKINASE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
TABLE 146. ASEAN UROKINASE MARKET SIZE, BY CARDIOVASCULAR SURGERY, 2018-2032 (USD MILLION)
TABLE 147. ASEAN UROKINASE MARKET SIZE, BY THROMBOLYTIC THERAPY, 2018-2032 (USD MILLION)
TABLE 148. ASEAN UROKINASE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 149. ASEAN UROKINASE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 150. GCC UROKINASE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 151. GCC UROKINASE MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
TABLE 152. GCC UROKINASE MARKET SIZE, BY RECOMBINANT UROKINASE, 2018-2032 (USD MILLION)
TABLE 153. GCC UROKINASE MARKET SIZE, BY FORM, 2018-2032 (USD MILLION)
TABLE 154. GCC UROKINASE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
TABLE 155. GCC UROKINASE MARKET SIZE, BY CARDIOVASCULAR SURGERY, 2018-2032 (USD MILLION)
TABLE 156. GCC UROKINASE MARKET SIZE, BY THROMBOLYTIC THERAPY, 2018-2032 (USD MILLION)
TABLE 157. GCC UROKINASE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 158. GCC UROKINASE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 159. EUROPEAN UNION UROKINASE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 160. EUROPEAN UNION UROKINASE MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
TABLE 161. EUROPEAN UNION UROKINASE MARKET SIZE, BY RECOMBINANT UROKINASE, 2018-2032 (USD MILLION)
TABLE 162. EUROPEAN UNION UROKINASE MARKET SIZE, BY FORM, 2018-2032 (USD MILLION)
TABLE 163. EUROPEAN UNION UROKINASE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
TABLE 164. EUROPEAN UNION UROKINASE MARKET SIZE, BY CARDIOVASCULAR SURGERY, 2018-2032 (USD MILLION)
TABLE 165. EUROPEAN UNION UROKINASE MARKET SIZE, BY THROMBOLYTIC THERAPY, 2018-2032 (USD MILLION)
TABLE 166. EUROPEAN UNION UROKINASE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 167. EUROPEAN UNION UROKINASE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 168. BRICS UROKINASE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 169. BRICS UROKINASE MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
TABLE 170. BRICS UROKINASE MARKET SIZE, BY RECOMBINANT UROKINASE, 2018-2032 (USD MILLION)
TABLE 171. BRICS UROKINASE MARKET SIZE, BY FORM, 2018-2032 (USD MILLION)
TABLE 172. BRICS UROKINASE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
TABLE 173. BRICS UROKINASE MARKET SIZE, BY CARDIOVASCULAR SURGERY, 2018-2032 (USD MILLION)
TABLE 174. BRICS UROKINASE MARKET SIZE, BY THROMBOLYTIC THERAPY, 2018-2032 (USD MILLION)
TABLE 175. BRICS UROKINASE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 176. BRICS UROKINASE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 177. G7 UROKINASE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 178. G7 UROKINASE MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
TABLE 179. G7 UROKINASE MARKET SIZE, BY RECOMBINANT UROKINASE, 2018-2032 (USD MILLION)
TABLE 180. G7 UROKINASE MARKET SIZE, BY FORM, 2018-2032 (USD MILLION)
TABLE 181. G7 UROKINASE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
TABLE 182. G7 UROKINASE MARKET SIZE, BY CARDIOVASCULAR SURGERY, 2018-2032 (USD MILLION)
TABLE 183. G7 UROKINASE MARKET SIZE, BY THROMBOLYTIC THERAPY, 2018-2032 (USD MILLION)
TABLE 184. G7 UROKINASE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 185. G7 UROKINASE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 186. NATO UROKINASE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 187. NATO UROKINASE MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
TABLE 188. NATO UROKINASE MARKET SIZE, BY RECOMBINANT UROKINASE, 2018-2032 (USD MILLION)
TABLE 189. NATO UROKINASE MARKET SIZE, BY FORM, 2018-2032 (USD MILLION)
TABLE 190. NATO UROKINASE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
TABLE 191. NATO UROKINASE MARKET SIZE, BY CARDIOVASCULAR SURGERY, 2018-2032 (USD MILLION)
TABLE 192. NATO UROKINASE MARKET SIZE, BY THROMBOLYTIC THERAPY, 2018-2032 (USD MILLION)
TABLE 193. NATO UROKINASE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 194. NATO UROKINASE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 195. GLOBAL UROKINASE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 196. UNITED STATES UROKINASE MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 197. UNITED STATES UROKINASE MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
TABLE 198. UNITED STATES UROKINASE MARKET SIZE, BY RECOMBINANT UROKINASE, 2018-2032 (USD MILLION)
TABLE 199. UNITED STATES UROKINASE MARKET SIZE, BY FORM, 2018-2032 (USD MILLION)
TABLE 200. UNITED STATES UROKINASE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
TABLE 201. UNITED STATES UROKINASE MARKET SIZE, BY CARDIOVASCULAR SURGERY, 2018-2032 (USD MILLION)
TABLE 202. UNITED STATES UROKINASE MARKET SIZE, BY THROMBOLYTIC THERAPY, 2018-2032 (USD MILLION)
TABLE 203. UNITED STATES UROKINASE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 204. UNITED STATES UROKINASE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 205. CHINA UROKINASE MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 206. CHINA UROKINASE MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
TABLE 207. CHINA UROKINASE MARKET SIZE, BY RECOMBINANT UROKINASE, 2018-2032 (USD MILLION)
TABLE 208. CHINA UROKINASE MARKET SIZE, BY FORM, 2018-2032 (USD MILLION)
TABLE 209. CHINA UROKINASE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
TABLE 210. CHINA UROKINASE MARKET SIZE, BY CARDIOVASCULAR SURGERY, 2018-2032 (USD MILLION)
TABLE 211. CHINA UROKINASE MARKET SIZE, BY THROMBOLYTIC THERAPY, 2018-2032 (USD MILLION)
TABLE 212. CHINA UROKINASE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 213. CHINA UROKINASE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)

Companies Mentioned

The key companies profiled in this Urokinase market report include:
  • Cerbios-Pharma SA
  • Guangdong Techpool Bio-Pharmaceutical Co., Ltd.
  • Hanways Chempharm
  • Kraeber & Co GmbH
  • LIVZON
  • Medac GmbH
  • Microbix Biosystems Inc.
  • Parchem Fine & Specialty Chemicals
  • Taj Pharmaceuticals Ltd.
  • Wanhua Biochem
  • Zydus

Table Information

Report AttributeDetails
No. of Pages194
PublishedJanuary 2026
Forecast Period2026 - 2032
Estimated Market Value ( USD ) in 2026 $ 2.07 Billion
Forecasted Market Value ( USD ) by 2032 $ 3.12 Billion
Compound Annual Growth Rate6.9%
Regions CoveredGlobal
No. of Companies Mentioned12

Related Topics

Related Reports

Urokinase Market Report 2025 - Product Image

Urokinase Market Report 2025

  • Report
  • 200 Pages
  • Global
From
Urokinase Market - Global Strategic Business Report - Product Image

Urokinase Market - Global Strategic Business Report

  • Report
  • 279 Pages
  • Global
From
2025 Global Forecast for Urokinase (2026-2031): High Tech Outlook Report - Product Image

2025 Global Forecast for Urokinase (2026-2031): High Tech Outlook Report

  • Report
  • 132 Pages
  • Global
From
Myocardial Infarction Treatment Enzyme Market - Global Forecast 2025-2030 - Product Image

Myocardial Infarction Treatment Enzyme Market - Global Forecast 2025-2030

  • Report
  • 181 Pages
  • Global
From
Thrombolytic Drug Market - Global Forecast 2026-2032 - Product Image

Thrombolytic Drug Market - Global Forecast 2026-2032

  • Report
  • 181 Pages
  • Global
From

About the Urokinase Market

Urokinase is a type of cardiovascular drug used to treat a variety of conditions, including pulmonary embolism, deep vein thrombosis, and acute myocardial infarction. It is a thrombolytic agent, meaning it works by breaking down blood clots and restoring blood flow to the affected area. Urokinase is administered intravenously and is typically used in combination with other medications. It is also used to prevent the formation of new blood clots. Urokinase is a widely used drug in the cardiovascular market, with a variety of manufacturers offering it in different forms. It is available in both generic and branded versions, with the latter being more expensive. The drug is also available in different concentrations, depending on the patient's needs. Some of the companies in the Urokinase market include Pfizer, Sanofi, Merck, and Bristol-Myers Squibb. Show Less Read more

Copyright © 2002-2026 Research and Markets. All Rights Reserved.